Clinical Trial News and Research

RSS

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

1 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ToleroMune(R) cat allergy treatment significantly reduced patients' symptoms in a recently completed, large-scale phase II clinical trial. The study also confirmed the treatment's highly favourable safety profile.

1 Feb 2011

FDA approves 'Cornell Dots' for first clinical trial in humans to diagnose cancer

"Cornell Dots" - brightly glowing nanoparticles - may soon be used to light up cancer cells to aid in diagnosing and treating cancer. The U.S. Food and Drug Administration has approved the first clinical trial in humans of the new technology.

1 Feb 2011

Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief

OXIS International, today announced highly favorable final results from an initial clinical study to assess the beneficial effects of its patent-pending ERGOFLEX joint health formula, launched commercially in December 2010.

1 Feb 2011

Favorable clinical results from Endologix's Nellix technology against EVAR

Endologix, developer of minimally invasive treatments for aortic disorders, announced today the publication of favorable clinical results for the Nellix technology for the endovascular repair of abdominal aortic aneurysm.

1 Feb 2011

Simple hTERT analysis may provide useful prognostic tool in advanced non-small cell lung cancer

High levels of circulating DNA may indicate faster progression of lung cancer and lower overall survival, according to a study published in the February edition of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).

1 Feb 2011

$FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma$

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and refractory multiple myeloma.

1 Feb 2011

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application from the US Food and Drug Administration for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.

31 Jan 2011

Oragenics to commence second phase 1 clinical trial for SMaRT Replacement Therapy

Florida-based biopharmaceutical company Oragenics, today announced its intention to commence a second phase 1 clinical trial of SMaRT Replacement Therapy.

31 Jan 2011

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Maxygen, a biotechnology company focused on the development of improved protein drugs, today announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic that is being developed by Perseid Therapeutics LLC, Maxygen's majority-owned subsidiary, in collaboration with Astellas Pharma Inc. for the treatment of rheumatoid arthritis and potentially other autoimmune indications.

31 Jan 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, is pleased to announce that the first group of patients receiving the lowest dose of SCIB1 in the Phase I clinical trial has been evaluated by the Cohort Review Committee.

31 Jan 2011

EU grants 3.3 million to AMP for gene therapy development against AIP

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Union has finalized a EUR 3.3 million grant to the AIPGENE consortium, of which AMT is a member, for the development of a gene therapy product for Acute Intermittent Porphyria.

31 Jan 2011

Chrissie Fletcher joins Pharma IQ to discuss about Health Technology Assessment

Chrissie Fletcher joined Pharma IQ to talk about Health Technology Assessment. In this comprehensive podcast, she discussed how she sees health economists and statisticians interacting going forwards, why there is so much emphasis on reporting for reimbursement and whether she expects pharma companies will try and do this more in-house, in the future.

29 Jan 2011

FDA approves Arteriocyte's Magellan MAR01 technology for Phase I trial to treat CLI

Arteriocyte, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Critical Limb Ischemia.

29 Jan 2011

Survey finds public lack knowledge of radiotherapy

Fewer than one in ten people think radiotherapy is a modern cancer treatment according to the results of a survey published Friday.

28 Jan 2011

Acurian completes enrollment contribution of over 600 diabetes patients for global, 9-protocol study

Acurian, Inc., a leading, full-service provider of patient recruitment and retention solutions, announced today at the Patient Recruitment & Retention for Diabetes & Obesity Studies Conference in Amsterdam that it recently completed its enrollment contribution of over 600 diabetes patients for a global, nine-protocol diabetes study.

28 Jan 2011

Arena reduces workforce by 25% and provides update on lorcaserin

Arena Pharmaceuticals, Inc. announced today a reduction of its US workforce of approximately 25%, or 66 employees. As a result of the workforce reduction, which Arena plans to complete around March 28, 2011, the company expects to incur restructuring charges, primarily in the first quarter of 2011, of approximately $3.8 million in connection with one-time employee termination costs.

28 Jan 2011

Boston Scientific reports first U.S. use of Blazer Open-Irrigated Catheter in BLOCk-CTI clinical trial

Boston Scientific Corporation today announced the first use of the Blazer® Open-Irrigated Catheter in the U.S. as part of the BLOCk-CTI clinical trial. BLOCk-CTI is a prospective, randomized trial evaluating the safety and effectiveness of the Blazer Open-Irrigated Catheter in patients with sustained or recurrent Type 1 atrial flutter.

28 Jan 2011

Clinical Trial News and Research

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

FDA approves 'Cornell Dots' for first clinical trial in humans to diagnose cancer

Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief

Favorable clinical results from Endologix's Nellix technology against EVAR

Simple hTERT analysis may provide useful prognostic tool in advanced non-small cell lung cancer

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

Oragenics to commence second phase 1 clinical trial for SMaRT Replacement Therapy

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

EU grants 3.3 million to AMP for gene therapy development against AIP

Chrissie Fletcher joins Pharma IQ to discuss about Health Technology Assessment

FDA approves Arteriocyte's Magellan MAR01 technology for Phase I trial to treat CLI

Survey finds public lack knowledge of radiotherapy

Acurian completes enrollment contribution of over 600 diabetes patients for global, 9-protocol study

Arena reduces workforce by 25% and provides update on lorcaserin

Boston Scientific reports first U.S. use of Blazer Open-Irrigated Catheter in BLOCk-CTI clinical trial

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News